Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Wall Street analysts forecast that Insulet (PODD) will report quarterly earnings of $0.81 per share in its upcoming release, pointing to a year-over-year increase of 11%. It is anticipated that revenues will amount to $541.33 million, exhibiting an increase of 22.6% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.With that in mind, let's delve into the average projections of some Insulet metrics that are commonly tracked and projected by analysts on Wall Street.The collective assessment of analysts points to an estimated 'Revenue- Total Omnipod' of $534.28 million. The estimate indicates a change of +23.4% from the prior-year quarter.Analysts predict that the 'Revenue- Drug Delivery' will reach $7.37 million. The estimate suggests a change of -15.3% year over year.Analysts expect 'Revenue- International Omnipod' to come in at $144.78 million. The estimate indicates a year-over-year change of +25.6%.The average prediction of analysts places 'Revenue- U.S. Omnipod' at $389.50 million. The estimate indicates a change of +22.6% from the prior-year quarter.View all Key Company Metrics for Insulet here>>>Over the past month, shares of Insulet have returned +4.8% versus the Zacks S&P 500 composite's +0.4% change. Currently, PODD carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Insulet Corporation (PODD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks